FOXO3公司
癌症研究
结直肠癌
转染
下调和上调
信号转导
化学
药理学
癌症
医学
蛋白激酶B
内科学
生物化学
基因
作者
Chao Liu,Yan Zhao,Jianing Wang,Yan Yang,Yan Zhang,Xinliang Qu,Sishi Peng,Zhaoying Yao,Shuli Zhao,Bangshun He,Qiong‐Yu Mi,Yubing Zhu,Xiuting Liu,Jianjun Zou,Xu Zhang,Qianming Du
出处
期刊:Cancer Letters
[Elsevier BV]
日期:2019-12-04
卷期号:470: 29-42
被引量:64
标识
DOI:10.1016/j.canlet.2019.11.042
摘要
5-fluorouracil (5-FU) is widely used in chemotherapy for colorectal cancer (CRC), but a high rate of chemoresistance reduces its effectiveness in clinical treatment. We found remarkably decreased expression of forkhead box 3 (FoxO3) protein, a tumor inhibitor, in 5-FU-resistant SW620 and HCT-8 (SW620/5-FU and HCT-8/5-FU) cells. Moreover, FoxO3 overexpression sensitized SW620/5-FU and HCT-8/5-FU cells to 5-FU. Mechanistically, FoxO3 inhibited the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway by directly binding to Keap1 promoter. Thioredoxin reductase 1 (TR1), a pivotal target gene of Nrf2, was observed to promote 5-FU resistance by reducing intracellular ROS levels. Clinical data also revealed that significant upregulation of TR1 was associated with poor outcome in CRC patients. Auranofin (AUR), a FoxO3 agonist and TR1 inhibitor, enhanced the sensitivity of HCT-8/5-FU and SW620/5-FU cells to 5-FU in vitro and in vivo. Taken together, our results suggest that FoxO3 could reverse 5-FU resistance in CRC via inhibiting the Nrf2/TR1 signaling pathway, and increasing the level of intracellular reactive oxygen species. Chemotherapeutic agents targeting FoxO3 and/or TR1, including AUR, might be promising adjuvant sensitizers to reverse chemoresistance in 5-FU-resistant CRC.
科研通智能强力驱动
Strongly Powered by AbleSci AI